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Summary This study tested the therapeutic efficacy of doxorubicin hydrochloride in two formulations: free in saline suspension and
encapsulated in polyethylene glycol-coated, long-circulating liposomes. The drug formulations at a dose level of 3 mg doxorubicin per kg body
weight were injected intravenously to treat the human pancreatic carcinoma AsPC-1, implanted s.c. into nude Swiss mice. Liposome-
encapsulated doxorubicin was significantly more effective in inhibiting tumour growth and in effecting cures, and had only minor systemictoxic
side-effects, indicated by a transient weight loss. Confocal laser scanning microscopy was used to determine the tumour uptake and the
clearance of doxorubicin in the free and in the liposomal forms. The liposome-encapsulated doxorubicin entered the tumour in greater
quantity, and remained in the tumour longer, than the free drug. The liposome formulation produced a sixfold or greater increase in
doxorubicin at the disease site. It is probable that increased penetration into the tumour, and long presence with slow drug release from
liposomes in the tumour, account for the enhanced therapeutic effect when the drug was encapsulated in polyethylene glycol-coated
liposomes.
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Studies in animal tumour models have found that the therapeutic
effects of anti-cancer drugs can be enhanced and the toxic side-
effects reduced when the drugs are encapsulated in liposomes
(Gabizon et al, 1985; Szoka, 1991). The effectiveness of drugs in
conventional liposomes is limited, however, by their rapid uptake
by the cells of the reticuloendothelial system (RES), reducing the
amount of the drug that reaches the tumour (Gabizon et al, 1991).
By covalently attaching polyethylene glycol (PEG) to the lipid
bilayers, smaller and more rigid liposomes are produced. PEG-
coated liposomes have a reduced uptake by the cells of the RES
and a longer circulation time (Allen et al, 1991), which, conse-
quently, results in an increased accumulation in tumours (Gabizon
et al, 1990; Huang et al, 1992).
When compared with doxorubicin in the regular saline formula-
tion or entrapped in conventional liposomes, the PEG-coated lipo-
some formulation shows increased therapeutic efficacy against
mouse mammary carcinomas (Vaage et al, 1992). Doxorubicin in
PEG-coated liposomes shows greater therapeutic efficacy against
xenografted human ovarian (Vaage et al, 1993) and prostatic
(Vaage et al, 1994) carcinomas than doxorubicin in the regular
saline formulation. A 95% lethal treatment of four weekly i.v.
injections of 9 mg kg-' doxorubicin in saline was reduced to 5%
mortality when the drug was in the liposome formulation (Vaage et
al, 1994). Empty liposomes were found to be without effect on
tumour growth (Vaage et al, 1992).
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The purpose of this investigation was to determine the uptakes
of doxorubicin by the tumours and to compare the relative thera-
peutic efficacies of doxorubicin in the regular saline formulation
or encapsulated in PEG-coated liposomes. The two drug formula-
tions were used against a human pancreatic carcinoma growing
s.c. in nude mice. Intraperitoneal tumour implantation and i.p.
therapy was not attempted in this pancreatic carcinoma in mouse
model because, in clinical disease, i.p. drug therapy after surgery
could interfere with the healing of intestinal anastomoses and is
therefore not a recommended procedure (Douglass et al, 1993).
The relative therapeutic efficacies of the two drug formulations
were determined by tumour incidences and by measuring tumour
volumes. We used confocal laser microscopy and the fluorescent
property of doxorubicin to compare formulation-dependent
uptakes of doxorubicin in tumours.
MATERIALS AND METHODS
Mice
The mice were line-bred, fully mature 18-week-old athymic nude
Swiss. All of the mice were raised and kept in a pathogen-free
environment, and were handled according to Roswell Park Cancer
Institute guidelines.
Tumour
The pancreatic adenocarcinoma AsPC-1 is the cell repository line
CRL 1682 from the ATCC collection of human tumours. In this
study, the tumour had an average doubling time of 18 days (from
50 mm3 to 100 mm3 in 18 days), and had a 100% probability of
growth in untreated mice.
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Figure 1 Quantitation by microfluorimetry of free doxorubicin in saline (F-
Dox) and doxorubicin encapsulated in polyethylene glycol-coated liposomes
(DOXIL) in 30-day s.c. implants of AsPC-1. The high-low spread in values
for DOXIL reflects adjustments for the fluorescence autoquenching of
encapsulated doxorubicin assuming that all doxorubicin was released (low
limit) or that all of the doxorubicin was encapsulated (high limit). The
autoquenching factor for encapsulated doxorubicin is 2.8. Each mouse
received 3.0 mg kg-' drug i.v. at 0 h
Drug uptake
Confocal laser scanning microscopy and microfluorimetry were
used to quantitate the uptakes of intravenously injected doxoru-
bicin in saline and liposomal doxorubicin by s.c. tumours that had
reached a size of 0.03-0.04 cm3, 30 days after implantation. The
tumours were excised 1, 2, 6, 16, 24, 48, 72, 120, 168 and 216 h
after the i.v. injection of 3.0 mg kg-' ofeach drug formulation. The
drug quantitations were made on cryostat sections of tumour, 15
,um thick. Sections were fixed in Carnoy's solution for 3 min,
washed in phosphate-buffered saline (PBS) for 30 s, and mounted
in Fluoromount-G (Southern Biotech. Associates, Birmingham,
AL, USA). The fluorescent images were analysed with a confocal
laser scanning microscope model LSM 210, (Carl Zeiss,
Thormwood, NY, USA). The excitation wavelength was 488 nm,
and the doxorubicin fluorescence was measured at 590 nm. A
semiquantitative determination ofdoxorubicin content per gram of
wet weight of tissue was made from comparisons with standard
curves of the fluorescence intensities of serial dilutions of free
doxorubicin and liposomal doxorubicin in agar gel. The fluores-
cence autoquenching factor for liposomal doxorubicin (deter-
mined from the standard curves) was 2.8±0.14 for all fluorescence
intensity levels.
Tumour implantation
AsPC-1 tumour tissue was removed from untreated donor
mice. The tissue was cut into 1-mm3 pieces and rinsed in cold
culture medium before two pieces were implanted s.c. through
incisions in the right and left posterior flanks of mice under the
short-acting inhalation anaesthetic Metofane (Pitman-Moore,
Mundelein, IL, USA).
Liposome components
The liposome components were: cholesterol (Croda, Fullerton,
CA, USA), hydrogenated soy phosphatidylcholine (HSPC)
(Lipoid, Ludwigshafen, Germany) and distearoyl-phosphatidyl-
ethanolamine (Genzyme, Cambridge, MA, USA) conjugated at its
amino position with a 1900 molecular weight fraction of metho-
xypoly(ethylene-glycol) (MPEG-1900-DSPE) as described by
Allen et al (1991).
Test materials
The drug preparations were doxorubicin hydrochloride (Adria-
mycin, Farmitalia Carlo Erba, Milan, Italy), 2.0 mg ml in saline
(F-Dox), and doxorubicin hydrochloride in polyethylene glycol-
coated liposomes (DOXIL). The doxorubicin concentration in
DOXIL was 2.0 mg ml and the drug encapsulation efficiency
was >90% as determined by gel permeation chromatography. The
mean particle size was 96 nm, determined by dynamic laser scat-
tering (Malvern Instruments, Malvern, UK). The ratio of mg
drug to mg total lipid was 1:8. Empty PEG-coated liposomes had
0.1 mol1% of the fluorescent phospholipid Texas Red phos-
phatidylethanolamine (Molecular Probes, Eugene, OR, USA)
incorporated in the lipid bilayer to determine the location of the
liposome vehicle in the tumour. All test materials were prepared
by SEQUUS Pharmaceuticals. Control mice received saline.
Treatment schedules
The drug formulations at dose levels of 3.0 mg of doxorubicin
hydrochloride per kg body weight were injected via a tail vein on
days 1, 8, 15, 22 and 29 after tumour implantation in volumes
ranging from 0.04 ml to 0.06 ml as determined by individual
weights. Mice with measurable tumours were killed by carbon
dioxide asphyxiation at the termination ofthe study, 85 days after
tumour implantation. Tumour-free mice were observed for an
additional month before the mice were killed and the tumour
implantation sites examined histologically for remaining viable
tumour. The heart, lungs, kidneys and liver were removed from all
of the mice at necropsy and examined histologically for evidence
of pathological changes.
Statistical analysis
The mice were randomly assigned to therapy and control groups.
Their weights, the incidence of tumour growth and the tumour
volumes were recorded weekly. Differences in tumour incidence
were evaluated with the 2 x 2 contingency test (Fisher's exact
test). The tumour volume was calculated by the formula 0.4(ab2)
where a was the larger and b the smaller diameter. Differences in
mean tumour volumes and differences in mean animal weights
were evaluated by Student's t-test. Fluorescence intensities are
measured in ten randomly selected 0.19-mm2 fields per cryostat
section. Differences in the mean fluorescence intensities were
evaluated by Student's t-test. Differences were considered signifi-
cant when the P-value of comparison was 0.05 or less.
RESULTS
Drug uptake
Previously untreated mice carried AsPC-1 implants that had
grown to 0.03-0.04 cm3 30 days after implantation. The fluori-
metric measurements of drug contents were made on cryostat
sections of tumours removed 1, 2, 6, 16, 24, 48, 72, 120, 168, and
British Journal ofCancer (1997) 75(4), 482-486 0 Cancer Research Campaign 1997484 J Vaage etal
I-
Figure 2 Scanning laser microscope images of 30-day s.c. implants of AsPC-1 showing the uptake of doxorubicin in polyethylene glycol-coated liposomes (not
adjusted for autoquenching) at 2 h (A) and at 24 h (C) and of free doxorubicin in saline at 2 h (B) and at 24 h (D). The drug, which appears as green and red, in
a colour scale of increasing concentrations, is primarily located in nuclei; original magnification x 40. (E) Transcytosis of doxorubicin in liposomes from a small
venule in a tumour removed 1 min after the i.v. injection of the drug; original magnification x 400. (F) Uptake of drug-free, Texas Red-labelled liposomes in a
tumour removed 24 h after the i.v. injection of the liposomes; original magnification x 63. The Texas Red fluorochrome appears green in the colour scale of
fluorescence intensities. The images are video prints from the laser microscope's computer disk storage
216 h after the i.v. injection of 3.0 mg kg-' doxorubicin in saline
and in PEG-coated liposomes. Figure 1 compares the quantities of
free doxorubicin and liposomal doxorubicin in the tumours. Free
doxorubicin was detectable for 24 h, liposomal doxorubicin was
detectable for 168 h. The relative values for the areas under the
curves were determined by measuring the trapezoidal areas
between time points. The value for free doxorubicin was 29. The
calculated values for liposomal doxorubicin gave a low limit of
165 (assuming that all ofthe drug had been released from the lipo-
somes, with no adjustment for autoquenching used to calculate the
values). The high limit was 462 (assuming that all ofthe drug was
encapsulated, and using the autoquenching factor 2.8 in the calcu-
lations). The actual proportion of encapsulated doxorubicin was
probably highest while the drug was accumulating in the tumour,
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Table 1 Pancreatic carcinoma AsPC-1 in nude mice. lncidencea of s.c.
growth with treatments on days 1, 8,15, 22, 29
Day
Treatment 15 29 43 57 71 85
Placebo (saline) 20/20 20/20 20/20 20/20 20/20 20/20
F-Dox 3 mg kg-' 18/20 18/20 19/20 19/20 19/20 19/20
DOXIL 3 mg kg-' 16/20 15/20 15/20 14/20 13/20 13/20b
alncidence of tumours per group of ten mice. Each mouse carried two tumour
pieces implanted s.c. in the right and left posterior flanks on day 0.
bSignificantly less than placebo (P = 0.0083) and F-Dox (P = 0.044). Placebo,
saline; F-Dox, free doxorubicin in saline; DOXIL, doxorubicin in
polyethylene-glycol-coated liposomes.
Time after tumour implantation (days)
Figure 3 The effects of treatments with saline (placebo), free doxorubicin in
saline (F-Dox) and doxorubicin in polyethylene glycol-coated liposomes
(DOXIL), on the growth of s.c. implants of tumour AsPC-1. Arrows indicate
the time points of treatment. Each mouse carried two tumour pieces
implanted s.c. in the right and left posterior flanks on day 0. The values are
the mean volumes of all tumours in each group of ten mice
and very low 168 h after injection. This means that the liposome
formulation had produced a sixfold or greater increase in the area
under the curve.
Figure 2A-D shows laser scan images of the distribution of free
doxorubicin and liposomal doxorubicin (direct readings, not
adjusted for auto-quenching) in tumours removed 2 and 24 h after
the i.v. injection of 3 mg kg-' doxorubicin in the two formulations.
The drug was primarily located in the nuclei of stromal and
tumour cells. The movement of doxorubicin from the blood into
the tumour, and the retention ofthe drug in the tumour, was greater
with liposomal doxorubicin than with free doxorubicin.
Figure 2E shows a segment of a venule inside an AsPC- 1
implant, removed min after the i.v. injection of 3 mg kg- lipo-
somal doxorubicin. The image indicates that the liposomes began
to move out of the circulation very soon. In the process, doxoru-
bicin accumulated in the endothelial nuclei.
The long persistence of doxorubicin in the stromal cells and
tumour cells when administered in liposomes, compared with the
rapid clearance of doxorubicin in saline, raised the question of
whether the liposomes, or only doxorubicin released from the lipo-
somes, entered into the cells. To study this question, drug-free
liposomes with the lipid phase labelled with the fluorochrome
Texas Red were prepared. Figure 2F shows that the labelled, drug-
free liposomes, injected i.v. in the same quantity as the liposomes
in a 3 mg kg-' dose of DOXIL, were located in the cytoplasm of
the stromal cells and tumour cells of an AsPC- 1 implant, removed
24 h after the injection of the liposomes.
Therapeutic effects
The therapeutic effects ofthe two drug formulations on the growth
of AsPC-1 implants were determined in two replicate tests. Each
test used five mice per group. The results were similar and the data
have been combined. The data on tumour growth are presented in
Figure 3 and the data on the incidences of measurable tumours are
presented in Table 1. The results show that liposomal doxorubicin
inhibited the growth of AsPC- more effectively than did the free
drug in saline, and resulted in a higher number of mice found
tumour free by necropsy and histological examination of tumour
implantation sites.
Toxicity
Free doxorubicin and liposomal doxorubicin caused average
losses of 3% body weight, which were recovered, respectively, 3
weeks and 5 weeks after the last treatment. Blood counts were
made from tail-vein punctures at the time ofthe last i.v. injections.
The mean total white counts and differential counts were within
the normal ranges in all treatment groups. Histological examina-
tion ofthe heart, lungs, kidneys and liver removed from all mice at
necropsy found no clear evidence of pathological changes in the
mice treated with the two doxorubicin formulations.
DISCUSSION
Earlier studies using human tumours implanted into nude mice
found that doxorubicin encapsulated in conventional liposomes
was no more effective therapeutically than doxorubicin suspended
in saline (Nagata et al, 1990; Papahadjopoulos et al, 1991). This
was also observed in a mouse mammary tumour model (Vaage et
al, 1992). PEG-coated liposomes are taken up by the RES less
readily than are conventional liposomes and therefore remain in
the circulation longer (Allen et al, 1991). This makes an increased
accumulation of liposomes in tumours possible (Papahadjopoulos
et al, 1991; Gabizon et al, 1990; Huang et al, 1992). In the present
study, the encapsulation of doxorubicin in liposomes increased
the therapeutic efficacy of the drug against a human pancreatic
carcinoma.
Using confocal laser scanning microscopy to measure the
content of doxorubicin in tumours, it was found that the uptake of
doxorubicin into the tumour was increased, and the presence ofthe
drug prolonged, when the drug was encapsulated in liposomes.
From the intratumour location of the liposomes, doxorubicin was
probably slowly released and the drug was maintained at an effec-
tive intracellular and extracellular cytotoxic level (Vichi and
Tritton, 1992) for a long period. It is likely that the long circulation
half-life of PEG-coated liposomes, in excess of 20 hours (Allen et
al, 1991), which enabled more ofthe liposomes to enterthe tumour,
and the long presence of the drug released from the liposomes
inside the tumour, are drug formulation characteristics responsible
for the therapeutic efficacy of DOXIL. Because five weekly i.v.
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injections of 3 mg kg-' doxorubicin in liposomes was a treatment
schedule that produced therapeutic benefit with no significant toxic
side-effects, the observed therapeutic advantage of polyethylene-
glycol coated liposomes as a vehicle for drug delivery has clinical
relevance as a potential new method in cancer drug therapy. In
view of the current opinion that 'In the absence of a clear cut
advantage of any therapy for pancreatic cancer, one must consider
chemotherapy for this disease still to be experimental' (Douglass et
al, 1993), the present observations on the therapeutic efficacy of
doxorubicin in liposomes against xenografts of a human pancreatic
carcinoma, and the low systemic toxicity, are encouraging.
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